MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease.

PubWeight™: 0.77‹?›

🔗 View Article (PMID 27320964)

Published in Toxicol Lett on June 15, 2016

Authors

Ayano Takeuchi-Yorimoto1, Yu Yamaura2, Masayuki Kanki2, Tetsuya Ide2, Ayumi Nakata3, Takahisa Noto4, Masahiro Matsumoto2

Author Affiliations

1: Drug Discovery Science & Management, Astellas Pharma Europe B.V., 2300 AH Leiden, The Netherlands; Drug Safety Research Labs, Astellas Pharma Inc., Ibaraki 305-8585, Japan. Electronic address: ayano.takeuchi@astellas.com.
2: Drug Safety Research Labs, Astellas Pharma Inc., Ibaraki 305-8585, Japan.
3: Drug Safety Research Division, Astellas Research Technologies Co., Ltd., Ibaraki 305-8585, Japan.
4: Drug Safety Research Labs, Astellas Pharma Inc., Ibaraki 305-8585, Japan; Non-clinical Research, Santen Pharmaceutical Co., Ltd., Nara 630-0101, Japan.